Earnings Call · Q4 FY2021·2022-02-28

Q4 21EPS +5.56%·Rev n/aQ3 21EPS +11.11%·Rev n/aQ2 21EPS +35.00%·Rev n/aQ1 21EPS +28.57%·Rev n/a⚠ consensus missing

LEXICON PHARMACEUTICALS, INC. LXRX

Disclaimer*

Chas Schultz

Lonnel Coats — Chief Executive Officer

Jeff Wade — President and Chief Financial Officer

−27.4%1d on move date−27.1% vs SPY3d−27.7%5d−25.3%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more LXRX calls or request research access.

More LXRX calls Browse calls Request research access